Halozyme Therapeutics, Inc. (HALO)
61.90
-0.75
(-1.20%)
USD |
NASDAQ |
Dec 11, 16:00
61.60
-0.30
(-0.48%)
After-Hours: 07:40
Halozyme Therapeutics Research and Development Expense (Quarterly): 17.25M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 3.552B |
| ANI Pharmaceuticals, Inc. | 12.30M |
| Bristol Myers Squibb Co. | 2.433B |
| Twist Bioscience Corp. | 17.01M |
| Aurinia Pharmaceuticals, Inc. | 8.435M |